会社概要

基本情報

• 社名: 武田薬品工業株式会社 (Takeda Pharmaceutical Company Limited)
• 代表者: Christophe Weber (President and CEO)

役員

• Masahiro Sakane (Chair of the Board)
• Emiko Higashi (External Director)
• Christophe Weber
• Masato Iwasaki
• Yoshiaki Fujimori
• Masahiro Sakane
• Toshiyuki Shiga
• Yasuhiko Yamanaka
• Shiro Kuniya
• Koji Hatsukawa
• Susan Kilsby
• Flemming Ornskov
• Thomas Dittrich
• Oliver Bohuon
• Ian Clark
• Gail Fosler
• Steven Gillis
• David Ginsburg
• Sara Mathew
• Albert Stroucken
• Christophe Weber – President & CEO
• Masahiro Sakane – Chair of the Board of Directors
• Emiko Higashi – External Director
• Masahiro Sakane – Chair of the Board of Directors
• Emiko Higashi – External Director

事業内容

Takeda is a global, values‑based, R&D‑driven biopharmaceutical company.

沿革

• 2018‑03‑28: UK Takeover Code Rule 8 notice to shareholders.\
• 2018‑04‑07: Statement regarding press reports.\
• 2018‑04‑19: General announcement.\
• 2018‑04‑20: Improved proposal for Shire plc announced.\
• 2018‑04‑24: Statement regarding Shire plc.\
• 2018‑04‑25: Extension of Shire’s proposal deadline to 8 May 2018.\
• 2018‑05‑08: Recommended offer for Shire plc; agreement to commence friendly acquisition; presentation on accelerating transformation; execution of bridge‑loan agreement.\
• 2018‑05‑09: Remarks by Chair Masahiro Sakane and external director Emiko Higashi at press conference.\
• 2018‑06‑01: Message from President & CEO Christophe Weber to shareholders about the recommended offer.\
• 2018‑06‑07: Statement regarding a press article.\
• 2018‑06‑08: Execution of term‑loan credit agreement and amendment to bridge‑credit agreement for the Shire acquisition.\
• 2018‑07‑10: Clearance received from the United States Federal Trade Commission.\
• 2018‑08‑06: Letter to Shire employees – update on integration planning.\
• 2018‑09‑14: Clearance received from China’s State Administration for Market Regulation.\
• 2018‑09‑27: Takeda R&D Investor Day (Tokyo).\
• 2018‑09‑28: Record date established for the extraordinary general meeting of shareholders.\
• 2018‑10‑18: Clearance received from the Japan Fair Trade Commission.\
• 2018‑10‑26: Execution of senior short‑term loan facility, subordinated syndicated loan, and second amendment to bridge‑credit agreement.\
• 2018‑10‑27: European Commission Phase 1 review update.\
• 2018‑11‑12: Publication of circular and notice of extraordinary general meeting of shareholders regarding the Shire acquisition.\
• 2018‑11‑15 – 2018‑11‑20: Pricing and issuance of unsecured senior notes (USD and EUR).\
• 2018‑12‑03 – 2018‑12‑06: Execution of loan agreement; shareholder approvals at Shire court and general meetings.\
• 2018‑12‑05: Shareholders approve resolutions related to the proposed acquisition of Shire plc.\
• 2018‑12‑19: Listing of American Depositary Shares on the New York Stock Exchange.\
• 2018‑12‑20: Cancellation of remaining commitments under the bridge‑credit agreement.\
• 2019‑01‑03: Court sanction of the scheme of arrangement for the Shire acquisition.\
• 2019‑01‑08: Completion of the acquisition of Shire plc – Takeda becomes a global, values‑based, R&D‑driven biopharmaceutical leader.\
• 2019‑01‑07: Notice regarding subscription requirements to issue new Takeda shares.\
• 2019‑01‑11: Announcement of applicable exchange rate under currency conversion facility.\
• 2020‑01‑08: Intention statements confirming the acquisition.

子会社・関連会社

• Shire plc
• Shire plc (wholly‑owned subsidiary as of 8 January 2019)
• Shire plc (wholly‑owned subsidiary, acquisition completed 8 Jan 2019)

お問い合わせ先

• メール: global.supplier.onboarding.operations@takeda.com

情報取得日時: 2026-01-01 17:13